BlueRock Therapeutics LP is a clinical stage cell therapy company that investigates the potential of cell therapy to replace cells damaged or lost to disease in order to create medicines in a new way. Self-described as striving to transform the treatment of degenerative diseases.

BlueRock Therapeutics LP

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.

Eterna Therapeutics Inc.

GC Therapeutics harnesses an induced pluripotent stem cell (iPSC) cellular programming platform to improve patient access across various therapeutic areas, focusing on gastrointestinal, neurological, and immunological diseases.

GC Therapeutics

PrivateFinancePartners is an independent financial advisor that supports clients in managing their life, career, and wealth through individual concepts and solutions.

Metric
Company Name	BlueRock Therapeutics LP	Eterna Therapeutics Inc.	GC Therapeutics	PrivateFinancePartners
Symbol		ERNA
MSH ID	COM:BLUEROCKTX	COM:ETERNATX	COM:GC-TX	DE:PFPARTNERS
Market	PRIVATE	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare	Healthcare & Health Services	Financial Services & Finance
Industry	Biotechnology	Biotechnology	Biotechnology	Financial Services
Country	US	US	US	DE
Stage			Series A
Employee Count		8		11
Website	bluerocktx.com	brooklynitx.com	gc-tx.com	pfpartners.de
LinkedIn				privatefinancepartners-gmbh
Founders

Metric
Market Cap	9.90M
Enterprise Value
Monthly Web Traffic	270.57K	1.68K
Web Traffic Growth	0.55	-0.43
Valuation
Raised Capital		65M

Metric
Revenue		68K
Revenue (LTM)
Revenue (NTM)
Gross Profit		-1.29M
EBITDA		-19.55M
Operating Income		-20.67M
Net Income		-21.67M
EPS		-4.08
Diluted EPS		-4.08
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		-5.88
Operating Profit Margin		-135.73
EBITDA Margin		-287.51
Net Profit Margin		-147.65
Return on Equity		15.58
Return on Assets		-0.44
Return on Capital Employed		-0.50

COM:BLUEROCKTX

BlueRock Therapeutics LP

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-0.42
P/B Ratio		2.34
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		192.73
EV Multiple		2.09

Metric
Days Sales Outstanding		12.71K
Days Payables Outstanding		4.45K
Days Inventory Outstanding
Operating Cycle		2.28K
Cash Conversion Cycle		1.79K
Asset Turnover		0.00

Metric
Operating Cash Flow		-20.41M
Free Cash Flow		-20.43M
Cash Flow to Debt		-0.38
Operating Cash Flow/Sales		-101.81
Free Cash Flow Yield		-2.54

Metric
Cash & Equivalents		7.58M
Accounts Receivable		527K
Inventory
Goodwill		2.04M
Debt to Capitalization		2.84
Debt to Assets		0.79
Current Ratio		0.73
Quick Ratio		1.22

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		28.90
R&D to Revenue		130.82
SG&A to Revenue		252.08